Skip to main content
OpenTrials
Completed

NCT Number: NCT05994313

STARchy Staples: a Randomised Controlled Trial on Cardiometabolic Health

An investigation into habitual potato consumption (mashed, boiled, baked) on sleep quality and chronic glycaemic control, established risk factors for cardiometabolic diseases, versus habitual consumptions of non-nutrient-dense starchy staples (white rice, pasta, and couscous).

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Nutritional Sciences, Franklin Wilkins Building, Waterloo campus.

Lambeth, London, SE1 9NH, United Kingdom

About this study

In the last few years, researchers have undergone efforts to conduct well-controlled trials to investigate the cardiometabolic health effect of consuming potatoes as part of a healthy diet. None to our knowledge, however, have investigated the harmful dyad of poor sleep and adverse glycaemic control, 2 interrelated factors which can exacerbate cardiometabolic (CM) health outcomes. The nutrient density of potatoes, namely being the single richest source of potassium per serving, provides a plausible mechanism in which the potatoes may act to improve health markers.

The primary objective of this study is to investigate whether consuming a portion of nutrient-dense potatoes in the evening meal, in place of other refined carbohydrates, can improve sleep quality, and improve nocturnal, and 24-hour, glycaemic control, both risk factors for CM diseases. Secondly, this study aims to investigate the effects of potato consumption on endothelium-dependent vasodilation, which can further interrelate to this web of interactions, and other measures of CM health.

Study design: A randomised, two-parallel arm, in-clinic and remote, 12-week dietary intervention study.

Study population: Healthy male and female 40-80-year-olds, who consume ≤4 fruits and vegetables per day and have sub-optimal sleep quality.

The study aims to recruit a total of 80 participants, allowing for an estimated 15% dropout rate, to reach 80% power at a significance level of 0.025 (based on two outcomes). The allocation ratio is 1:1 intervention to control.

Statistical analysis: Differences between groups (minimized for age, gender, BMI) will be analysed using Linear mixed models for outcomes with 3 timepoints (urinary outcomes, dietary intake data), with change being the dependent factor, subject ID as a random effect, treatment and season as fixed effects, and baseline outcome and BMI as covariates. Variables with 2 timepoints will be assessed with an ANCOVA regression model.

Locations:

Metabolic Research Unit, 4th floor, Franklin Wilkins Building, Waterloo campus, Kings College London, SE1 9NH.

Screening assessment: Participants will be initially assessed for suitability against the inclusion-exclusion criteria via an online questionnaire. The outputs of the questionnaire will be assessed by the study team. Some exclusion criteria will be assessed at the baseline clinic visit before any baseline measures are provided.

Study duration: There will be a 2-week run-in period, followed by a 12-week dietary intervention.

Dietary intervention: The intervention (potato group) will consume at least 230 g of white potatoes (including fresh and frozen baked, boiled, and mashed potato products) in their evening meal, providing ~1000 mg potassium, enough to increase national median intakes up to recommended intakes. The control group will consume isoenergetic amounts of non-nutrient-dense starchy staples (white pasta, white rice, or couscous).

Although participants cannot be blinded to what they're consuming, they will be blinded to whether they are in the control or the intervention group, to reduce the risk of bias.

Participants will be required to source the potatoes and make these meals themselves, however, they will be provided with rotating 4-weekly recipe cards, with instructions on how to prepare meals.

Participants will be required to attend several virtual one-to-ones with the study team, including an introductory call, a virtual run-in induction where they will be run through the study equipment, and 2 in-person clinic visits. Participants will be responsible for applying some study equipment from home, to reduce clinic visits and improve study retention.

Compliance: Compliance will be monitored via several methods. Firstly, 24 h urinary potassium excretion, which is shown to recover 75% of potassium intake, secondly self-reported compliance will be measured through evening meal checklists. We also plan to use dietary recalls at weeks 2, 4, and 8 to reinforce dietary advice, and to make adaptations to rotating menus based on individual needs, if participants are struggling with adherence. Detailed dietary intake will be assessed through 4-day food diaries at weeks 0, 6, and 12- this data will be used for analysis.

Flow-mediated dilation: A Doppler ultrasound will be utilised to capture continuous ultrasound videos to measure flow-mediated dilation. These will be analysed with automated software provided by Maastricht University.

Anthropometry: Weight, height, waist and hip circumference, blood pressure, and body fat will be taken using standard procedures, in duplicates by a trained researcher at baseline and endline clinic visits.

Blood samples: Fasting blood samples will be collected from a superficial antecubital vein via venepuncture before and after the dietary intervention, by a trained researcher.

Participants will be asked to record and monitor the following information:

Self-reported compliance with dietary intervention, weekly weight (data diaries), and habitual dietary intake (4-day diet diaries).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Self-reported healthy adults
  • Aged 40-80 years old
  • Intake of ≤4 portions of fruits and vegetables (excluding potatoes) per day
  • Low sleep quality index of >5 (Pittsburgh sleep quality index).

Exclusion criteria

  • Shift workers and those with multiple jobs or carers who are required to wake through the night
  • Unwilling to refrain from dietary supplements
  • Unwilling to follow protocol and/or give informed consent
  • Diagnosed with Cardiovascular Disease (CVD), Type 2 Diabetes, Celiac disease, Insomnia, Sleep apnoea
  • Presence of gastrointestinal disorder
  • Users of drugs that are likely to alter gastrointestinal motility or nutrient absorption
  • History of substance abuse or alcoholism
  • Currently pregnant, planning pregnancy, breastfeeding, or having had a baby 12 months prior
  • Weight change of >3kg in the preceding 2 months
  • BMI <18.5kg/m2 or > 35kg/m2,
  • Current smokers, or individuals who quit smoking in the last 6-months
  • Frequently consume wholemeal products (1-2 times per day, in the short screening FFQ)
  • Never consumed refined starchy staples, such as white pasta or rice (rarely or never, in the short screening FFQ)
  • High potato consumption (4-6 times per week, in the short screening FFQ)
  • High risk of obstructive sleep apnoea (answer yes to >3 questions, in STOP-Bang questionnaire)
  • Vegetarian, Vegan, or pescatarian dietary preferences.
  • Diagnosed with mental health disorders, and/or on medicine for their mental health (antipsychotics, antidepressants, beta-blockers)
  • Chronic user of antihistamines
  • Fasting glucose >7mmol/l (finger prick test at baseline clinic)
  • Is taking weight loss, or glucose regulating medications.
  • Has been unstable on blood pressure lowering medications for at least 3-months prior to enrollment.

Treatment and study plan

Habitual potato consumption

Dietary Supplement

Potatoes are to be consumed in the evening meal, every evening for 12-weeks.

Habitual non-nutrient-dense staple consumption

Dietary Supplement

White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.

Primary outcomes

  1. Change in 7-day sleep efficiency

    Time frame: Pre- and post-intervention: 12 weeks

    Differences in % sleep efficiency at endline vs baseline. Sleep efficiency % is described as the total time spent asleep/ total time spent in bed x 100.

  2. Change in 12-day nocturnal mean glucose

    Time frame: Pre- and post-intervention: 12 weeks

    Differences in mean nocturnal glucose, measured using a Freestyle Libre 3 continuous glucose monitor.

Secondary outcomes

  1. Change in mean nocturnal AUC

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day mean nocturnal Area Under the Curve (AUC).

  2. Difference in nocturnal TIR

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day nocturnal Time In Range for non-diabetic populations (TIR nd).

  3. Change in the nocturnal CV%

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day nocturnal coefficient of variation (CV%)

  4. Change in nocturnal MAGE

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day nocturnal Mean Amplitude of Glycemic Excursions (MAGE).

  5. Change in nocturnal MODD

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day nocturnal Mean of Daily Differences (MODD).

  6. Change in mean daytime glycaemic control

    Time frame: Pre- and post-intervention: 12 weeks

    Differences in 12-day mean daytime glucose.

  7. Difference in daytime TIR

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day daytime Time In Range for non-diabetic populations (TIR nd).

  8. Change in the daytime CV%

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day daytime coefficient of variation (CV%)

  9. Change in daytime MAGE

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day daytime Mean Amplitude of Glycemic Excursions (MAGE).

  10. Change in daytime MODD

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day daytime Mean of Daily Differences (MODD).

  11. Change in mean 24-hour glycaemic control

    Time frame: Pre- and post-intervention: 12 weeks

    Differences in 12-day mean 24-hour glucose.

  12. Difference in 24-hour TIR

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day 24-hour Time In Range for non-diabetic populations (TIR nd).

  13. Change in the 24-hour CV%

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day 24-hour coefficient of variation (CV%)

  14. Change in 24-hour MAGE

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day 24-hour Mean Amplitude of Glycemic Excursions (MAGE).

  15. Change in 24-hour MODD

    Time frame: Pre- and post-intervention: 12 weeks

    Difference in 12-day 24-hour Mean of Daily Differences (MODD).

  16. Change in heart rate variability during mental stress

    Time frame: Pre- and post-intervention: 12 weeks

    A combination of time domain, frequency domain and non-linear methods (NN intervals, heart rate, rMSSD, pNN50, SDNN, TINN, SDANN, SD1/SD2, High Frequency, Low Frequency, Very Low Frequency, Ultra Low Frequency HF:LF, total power), will be compared from pre- to post-mental stress.

  17. Change in 24-hour heart rate variability

    Time frame: Pre- and post-intervention: 12 weeks

    A combination of time domain, frequency domain and non-linear methods (NN intervals, heart rate, rMSSD, pNN50, SDNN, TINN, SDANN, SD1/SD2, High Frequency, Low Frequency, Very Low Frequency, Ultra Low Frequency HF:LF, total power).

  18. Change in Endothelial function

    Time frame: Pre- and post-intervention: 12 weeks

    Mean differences in flow-mediated dilation (%)

  19. Nocturnal continuous blood pressure

    Time frame: Whole 12 week period.

    Measured with an Aktiia Photoplethysmography watch.

  20. Daytime continuous blood pressure

    Time frame: Whole 12 week period.

    Measured with an Aktiia Photoplethysmography watch.

  21. Change in blood pressure

    Time frame: Pre- and post-intervention: 12 weeks

    Diastolic and systolic blood pressure, measured by oscillometry.

  22. Change in plasma lipids

    Time frame: Pre- and post-intervention: 12 weeks

    Including: total lipids, HDL and LDL-cholesterol, and Triacylglycerols.

  23. Change in fasting plasma glucose

    Time frame: Pre- and post-intervention: 12 weeks

    Fasting plasma glucose concentration

  24. Change in fasting insulin

    Time frame: Pre- and post-intervention: 12 weeks

    Fasting insulin concentration

  25. Change in fasting HbA1C

    Time frame: Pre- and post-intervention: 12 weeks

    Fasting HbA1C concentration

  26. Change in serum potassium

    Time frame: Pre- and post-intervention: 12 weeks

    Serum potassium mmol/L

  27. Change in sleep duration, in minutes

    Time frame: Pre- and post-intervention: 12 weeks

    Sleep duration (minutes)

  28. Change in sleep duration, in %

    Time frame: Pre- and post-intervention: 12 weeks

    Sleep duration (%)

  29. Change in sleep latency

    Time frame: Pre- and post-intervention: 12 weeks

    Sleep latency is defined as the time it takes to fall asleep from the time intended to fall asleep.

  30. Change in body fat %

    Time frame: Pre- and post-intervention: 12 weeks

    Body fat % measured using TANITA bioelectrical impedance scales

  31. Change in waist circumference (cm)

    Time frame: Pre- and post-intervention: 12 weeks

    Waist circumference (cm)

  32. Change in BMI kg/m2

    Time frame: Pre- and post-intervention: 12 weeks

    BMI kg/m2, measured using a stadiometer and TANITA scales

  33. Calystegine potato biomarker

    Time frame: Pre- and post-intervention: 12 weeks

    Calystegine will be analysed as an exploratory biomarker of potato consumption (a polyhydroxylated nortropane alkaloid), by Triple Quadrupole mass spectrometry (MS/MS).

Sponsors and collaborators

Lead sponsor

King's College London

Other

Collaborators

  • Alliance for Potato Research and Education
  • Maastricht University

Registry information

Acronym: STARCHy

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 16, 2023
Registry last updated
Sep 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.